首页> 美国卫生研究院文献>other >Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone
【2h】

Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone

机译:聚谷氨酸定向用于骨诱导信号对同种异体移植骨递送的生物活性肽的偶联

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Allograft bone is commonly used as an alternative to autograft, however allograft lacks many osteoinductive factors present in autologous bone due to processing. In this study, we investigated a method to reconstitute allograft with osteoregenerative factors. Specifically, an osteoinductive peptide from collagen I, DGEA, was engineered to express a heptaglutamate (E7) domain, which binds the hydroxyapatite within bone mineral. Addition of E7 to DGEA resulted in 9× greater peptide loading on allograft, and significantly greater retention after a 5-day interval with extensive washing. When factoring together greater initial loading and retention, the E7 domain directed a 45-fold enhancement of peptide density on the allograft surface. Peptide-coated allograft was also implanted subcutaneously into rats and it was found that E7DGEA was retained in vivo for at least 3 months. Interestingly, E7DGEA peptides injected intravenously accumulated within bone tissue, implicating a potential role for E7 domains in drug delivery to bone. Finally, we determined that, as with DGEA, the E7 modification enhanced coupling of a bioactive BMP2-derived peptide on allograft. These results suggest that E7 domains are useful for coupling many types of bone-regenerative molecules to the surface of allograft to reintroduce osteoinductive signals and potentially advance allograft treatments.
机译:同种异体移植骨通常用作自体移植的替代物,但是由于加工,同种异体移植缺乏自体骨中存在的许多骨诱导因子。在这项研究中,我们研究了一种用骨再生因子重建同种异体移植的方法。具体来说,来自胶原蛋白I的骨诱导肽DGEA被工程化以表达七谷氨酸(E7)域,该域结合骨矿物质中的羟基磷灰石。在DGEA中添加E7会导致同种异体移植物中的肽负载量增加9倍,并且在5天间隔内进行大量洗涤后,其保留力明显提高。当一起考虑更大的初始负载和保留时,E7结构域指导同种异体移植表面上肽密度提高45倍。还将肽包被的同种异体移植物皮下植入大鼠中,发现E7DGEA在体内保留了至少3个月。有趣的是,静脉内注射的E7DGEA肽积聚在骨组织内,这暗示了E7结构域在药物输送至骨中的潜在作用。最后,我们确定,与DGEA一样,E7修饰增强了同种异体移植物中生物活性BMP2衍生肽的偶联。这些结果表明,E7结构域可用于将许多类型的骨再生分子偶联至同种异体移植物表面,以重新引入骨诱导信号并潜在地促进同种异体移植治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号